We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serological Assays Assessed for Q Fever

By LabMedica International staff writers
Posted on 24 Oct 2012
A quality assessment was performed for three different serological methods that are routinely used in the diagnosis of Q fever. More...


The indirect immunofluorescence assay (IFA) is considered the reference method for diagnosing Q fever, but serology is also performed by complement fixation assay (CFA) or enzyme-linked immunosorbent assay (ELISA), however, comparability between these assays is not clear.

A total of 13 laboratories collaborated in multi-institution study to test the various methods and the results were collated by the Center for Infectious Disease Control, (RIVM; Bilthoven, The Netherlands). The Q fever cases were confirmed either by a positive polymerase chain reaction (PCR) or by seroconversion. In total, the proficiency panel consisted of 25 serum samples: five samples with an intended negative outcome, six samples from acute Q fever patients, and eight serially diluted high-positive sample from a Q fever patient.

The five Dutch laboratories that performed IFA all used the same commercially available IFA (Focus Diagnostics, Cypress, CA, USA). Six laboratories carried out a commercially available CFA (Virion-Serion; Würzburg, Germany), and five participants also performed the Virion-Serion's ELISA and one laboratory used an ELISA from Inverness Medical Innovations, (Waltham, MA, USA). Three national reference laboratories from outside the Netherlands also participated and all used an in-house IFA.

For the diagnosis of Q fever, all assays reached a specificity of 95% to 100% in the samples with an intended negative outcome. All laboratories correctly identified Q fever patients with the algorithm of the methods that were applied. The IFA, ELISA, and CFA values between laboratories using the same methods were within close range, with usually no more than two dilution differences in the reported titer. However, there were differences in sensitivity between the methods.

The IFA proved to be the most sensitive assay in detecting a past Q fever infection. All laboratories using IFA detected both immunoglobulin G (IgG) phase I antibodies (titers ranged from 1:32 to1:256) and phase II antibodies (titers ranged from1:128 to 1:512) in samples in these patients. The ELISA yielded mostly intermediate IgG phase II responses, and four of six laboratories using CFA detected only low titers of 1:10 to1:20 against phase II. No IgM response was detected with any of the applied assays.

Q fever is a highly contagious zoonotic disease caused by Coxiella burnetii, a Gram-negative obligate intracellular bacterium. Since 2007, the Netherlands has been faced with the largest outbreak of Q fever ever reported, with over 4,000 notified cases. The authors concluded that IFA, ELISA, and CFA are all suitable serodiagnostic assays for diagnosing acute Q fever. ELISAs can be an alternative for screening large sample numbers. The IFA appears to be the method of choice when high sensitivity is required, especially against phase I, and for example identifying chronic Q fever. The study was published on October 5, 2012, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Netherlands Center for Infectious Disease Control
Focus Diagnostics
Virion-Serion



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.